Staphylococcus aureus (S. aureus) is a gram-positive bacterium and a causative agent of healthcare-associated infections from both community-acquired and hospital-acquired bacteremia. It causes a wide range of diseases from mild to a life-threatening condition, and a leading cause of bacteremia and infective endocarditis (IE). It can cause multiple infections, such as lung (pneumonia, influenza-associated), skin (moderately severe, rarely necrotizing fasciitis), bone (osteomyelitis), bloodstream (bacteremia), specific toxin-related diseases (toxic shock syndrome, foodborne illness), and others. S. aureus Bacteremia (SAB) are among the most prevalent and difficult to treat the condition with higher morbidity and mortality. S. aureus most often spreads by contaminated hands. The breaching of the skin and mucous membranes may give access to S. aureus to enter underlying tissues or the bloodstream. In recent years, the incidence of S. aureus bacteremia and its complications has increased sharply due to increased frequency of invasive procedures, immunocompromised patients, and increased resistance of S. aureus strains to available antibiotics.

 

 

 

 

 

 

 

1.  S. aureus bacteremia is estimated with an incidence rate ranging from 20 to 50 cases per 100,000 population per year (Vanhal et al.). Even though overall rates of SAB may have stabilized, the incidence of MRSA bacteremia has increased dramatically in recent years in both the US and Europe.

 

2. According to a study by Atrouni et al., out of 247 evaluable adult patients with S. aureus, the episodes of bacteremia were classified according to acquisition type, in which 23.5% were nosocomial (N-SAB), 58.7% were healthcare-associated (HCA-SAB), and 17.8% were community-acquired (CA-SAB).

 

“According to DelveInsight’s analysis, male gender is consistently associated with increased SAB incidence with male-to-female ratios of ∼1.5. The basis for this increased risk is not understood”

1. Basilea Pharmaceutica Co.

 

1. Ceftobiprole

2. NDV-3A

 

1. Key Insights

2. Executive Summary of Staphylococcus aureus Bacteremia

3. Competitive Intelligence Analysis for Staphylococcus aureus Bacteremia

4. Staphylococcus aureus Bacteremia: Market Overview at a Glance

4.1. Staphylococcus aureus Bacteremia Total Market Share (%) Distribution in 2017

4.2. Staphylococcus aureus Bacteremia Total Market Share (%) Distribution in 2030

5. Staphylococcus aureus Bacteremia: Disease Background and Overview

6. Patient Journey

7. Staphylococcus aureus Bacteremia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Staphylococcus aureus Bacteremia Treatment and Management

8.2. Staphylococcus aureus Bacteremia Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Staphylococcus aureus Bacteremia Treatment

11. Marketed Products

12. Emerging Therapies

13. Staphylococcus aureus Bacteremia: Seven Major Market Analysis

13.1. Key Findings

13.2. Staphylococcus aureus Bacteremia Market Size in 7MM

13.3. Staphylococcus aureus Bacteremia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Staphylococcus aureus Bacteremia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

• The report will help in developing business strategies by understanding trends shaping and driving the Staphylococcus aureus Bacteremia market
• To understand the future market competition in the Staphylococcus aureus Bacteremia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Staphylococcus aureus Bacteremia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Staphylococcus aureus Bacteremia market
• To understand the future market competition in the Staphylococcus aureus Bacteremia market

Related Reports:- 

1. Staphylococcus Aureus Bacteremic Pneumonia – Epidemiology Forecast to 2030

2. Staphylococcus Aureus Infection – Epidemiology Forecast to 203